Zobrazeno 1 - 10
of 3 228
pro vyhledávání: '"Dipeptidyl peptidase‐4 inhibitor"'
Autor:
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhib
Externí odkaz:
https://doaj.org/article/3c30aa10af6145a49ad751da66897f47
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Following the introduction of incretin-based drugs to the market, instances of acute pancreatitis have been reported, leading the FDA to mandate a warning label. Incretin-based therapy has been linked to a rare yet significant adverse e
Externí odkaz:
https://doaj.org/article/d82946e4340246c4adb8003cd2f5bd22
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 1, Pp 226-232 (2024)
Abstract Background The prognosis of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid (DPP‐4i‐BP) is variable, with some cases showing spontaneous remission after drug cessation and others showing worsening BP or developing infe
Externí odkaz:
https://doaj.org/article/2e125e55b52e48649ee7df9e59d461e3
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 39, Iss 10, Pp 1038-1044 (2023)
Abstract Several studies have reported an association between dipeptidyl peptidase 4 inhibitor (DPP4i), a commonly prescribed second‐line oral antihyperglycemic drug, and bullous pemphigoid (BP). However, the benefits of DPP4i withdrawal in patient
Externí odkaz:
https://doaj.org/article/5ea5f65044694fecbc777b8e688e969c
Autor:
Midori Sunada, Seiko Sugiyama, Yukiko Nakahara, Mariko Yamane, Rehito Mashiko, Takenobu Yamamoto, Yumi Aoyama
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 3, Pp 479-487 (2023)
Abstract Background Many reports have described the development of bullous pemphigoid (BP) following COVID‐19 vaccination. In dipeptidyl peptidase‐4 inhibitor‐associated BP (DPP‐4i‐BP), cessation of DPP‐4i appears to have a paradoxical ef
Externí odkaz:
https://doaj.org/article/f1d19178bb97485e824d85aaa316d9b9
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Introduction: Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development o
Externí odkaz:
https://doaj.org/article/19d885e42bec45008bbfca4122bf4ee5
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 32, Iss , Pp 101957- (2023)
Purpose: To report a rare Ocular Cicatricial Pemphigoid (OCP) case in a patient taking a Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor), a medication used for the management of type 2 diabetes, for at least six years. Observations: A 64-year-old
Externí odkaz:
https://doaj.org/article/59edd01299f947d8988f8ff112966b81
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 16, Pp 31-36 (2023)
Chun-Feng Huang,1– 3 Tso-Yen Mao,3 Shinn-Jang Hwang1,2 1Division of Family Medicine, En Chu Kong Hospital, New Taipei City, Taiwan, Republic of China; 2Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwa
Externí odkaz:
https://doaj.org/article/0205d2c0f4c14dfebe50484ee77e8639
Autor:
Sodai Kubota, Takuya Haraguchi, Hitoshi Kuwata, Yusuke Seino, Kenta Murotani, Takumi Tajima, Gen Terashima, Makiko Kaneko, Yoshihiro Takahashi, Ken Takao, Takehiro Kato, Kenichiro Shide, Saeko Imai, Atsushi Suzuki, Yasuo Terauchi, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 1, Pp 67-74 (2023)
ABSTRACT Aims/Introduction This study was designed and carried out to investigate the association of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use with pancreatic cancer (PC) in individuals with diabetes in Japan. Materials and Methods The JMDC C
Externí odkaz:
https://doaj.org/article/8fd79467e1a14780b953b0a7c7b9434d
Autor:
Shangyu Chai, Ruya Zhang, Richard David Carr, Carolyn F. Deacon, Yiman Zheng, Swapnil Rajpathak, Jingya Chen, Miao Yu
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimsGlucose-dependent insulinotropic polypeptide (GIP) confers a variety of metabolic benefits in type 2 diabetes mellitus (T2DM). This meta-analysis was conducted to investigate the impact of dipeptidyl peptidase 4 (DPP4) inhibitors on GIP levels in
Externí odkaz:
https://doaj.org/article/c5d6fcb6c29c4a16a44ab5511b0fe22d